NLS Pharmaceutics (NLSP) CEO Issues Letter to Shareholders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to NLS Pharmaceutics (NLSP) CEO Issues Letter to Shareholders

NLS Pharmaceutics CEO Issues Letter to Shareholders

December 11, 2024 7:32 AM EST

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:

Dear Valued Shareholders,

As we move forward with exciting developments at NLS, I want to update you on the significant progress we've made, key challenges we've overcome,... More